Nishino Yasuhiro, Webb Ian G, Davidson Sean M, Ahmed Aminul I, Clark James E, Jacquet Sebastien, Shah Ajay M, Miura Tetsuji, Yellon Derek M, Avkiran Metin, Marber Michael S
King's College London BHF Centre, Cardiovascular Division, The Rayne Institute, St. Thomas' Hospital, UK.
Circ Res. 2008 Aug 1;103(3):307-14. doi: 10.1161/CIRCRESAHA.107.169953. Epub 2008 Jun 26.
The inactivation of glycogen synthase kinase-3beta (GSK-3beta) is proposed as the event integrating protective pathways initiated by preconditioning and other interventions. The inactivation of GSK-3 is thought to decrease the probability of opening of the mitochondrial permeability transition pore. The aim of this study was to verify the role of GSK-3 using a targeted mouse line lacking the critical N-terminal serine within GSK-3beta (Ser9) and the highly homologous GSK-3alpha (Ser21), which when phosphorylated results in kinase inactivation. Postconditioning with 10 cycles of 5 seconds of reperfusion/5 seconds of ischemia and preconditioning with 6 cycles of 4 minutes of ischemia/6 minutes of reperfusion, similarly reduced infarction of the isolated perfused mouse heart in response to 30 minutes of global ischemia and 120 minutes of reperfusion. Preconditioning caused noticeable inactivating phosphorylation of GSK-3. However, both preconditioning and postconditioning still protected hearts of homozygous GSK-3 double knockin mice. Moreover, direct pharmacological inhibition of GSK-3 catalytic activity with structurally diverse inhibitors before or after ischemia failed to recapitulate conditioning protection. Nonetheless, cyclosporin A, a direct mitochondrial permeability transition pore inhibitor, reduced infarction in hearts from both wild-type and homozygous GSK-3 double knockin mice. Furthermore, in adult cardiac myocytes from GSK-3 double knockin mice, insulin exposure was still as effective as cyclosporin A in delaying mitochondrial permeability transition pore opening. Our results, which include a novel genetic approach, suggest that the inhibition of GSK-3 is unlikely to be the key determinant of cardioprotective signaling in either preconditioning or postconditioning in the mouse.
糖原合酶激酶-3β(GSK-3β)的失活被认为是整合预处理和其他干预措施所启动的保护途径的事件。GSK-3的失活被认为会降低线粒体通透性转换孔开放的概率。本研究的目的是使用一种靶向小鼠品系来验证GSK-3的作用,该品系缺乏GSK-3β(Ser9)和高度同源的GSK-3α(Ser21)内的关键N端丝氨酸,磷酸化后会导致激酶失活。用10个周期的5秒再灌注/5秒缺血进行后处理,以及用6个周期的4分钟缺血/6分钟再灌注进行预处理,同样减少了离体灌注小鼠心脏在30分钟全心缺血和120分钟再灌注后的梗死面积。预处理导致GSK-3明显的失活磷酸化。然而,预处理和后处理仍然对纯合GSK-3双敲入小鼠的心脏起到保护作用。此外,在缺血前后用结构多样的抑制剂直接药理学抑制GSK-3催化活性未能重现预处理保护作用。尽管如此,环孢素A,一种直接的线粒体通透性转换孔抑制剂,减少了野生型和纯合GSK-3双敲入小鼠心脏的梗死面积。此外,在GSK-3双敲入小鼠的成年心肌细胞中,胰岛素暴露在延迟线粒体通透性转换孔开放方面仍然与环孢素A一样有效。我们的结果,包括一种新的基因方法,表明抑制GSK-3不太可能是小鼠预处理或后处理中心脏保护信号的关键决定因素。